“`html
The average one-year price target for Co-Diagnostics (MUN:C97) is now €1.76 per share, a decrease of 32.24% from the prior estimate of €2.59 dated October 29, 2025. The current price targets from analysts range from a low of €0.87 to a high of €2.71, which represents a potential increase of 1,252.44% from the last reported closing price of €0.13 per share.
As of the latest quarter, 44 funds or institutions report positions in Co-Diagnostics, a decrease of 12% from the previous quarter. Total shares owned by institutions have declined by 17.10% over the last three months to 5,119K shares. Notable shareholders include Vanguard Total Stock Market Index Fund (1,276K shares, 2.65% ownership) and Renaissance Technologies (561K shares, 1.17% ownership), which recently increased its holdings by 1.91%.
“`
